Fax: (646) 962 1605
Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma
Article first published online: 27 JUL 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 23, pages 5432–5439, 1 December 2010
How to Cite
Furman, R. R., Martin, P., Ruan, J., Cheung, Y.-K. K., Vose, J. M., LaCasce, A. S., Elstrom, R., Coleman, M. and Leonard, J. P. (2010), Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma. Cancer, 116: 5432–5439. doi: 10.1002/cncr.25509
- Issue published online: 23 NOV 2010
- Article first published online: 27 JUL 2010
- Manuscript Revised: 23 MAY 2010
- Manuscript Received: 15 MAR 2010
- Manuscript Accepted: 7 JUN 2009
- and prednisone (CHOP);
- diffuse large B-cell lymphoma;
- mantle cell lymphoma;
- non-Hodgkin lymphoma;
- maximum tolerated dose;
Bortezomib has preclinical and clinical in B-cell lymphomas, both alone and in combination with other agents. A phase 1 evaluation was conducted of bortezomib with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with untreated diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
Twenty patients (16 with DLBCL and 4 with MCL) with a median age of 66 years (range, 29-84 years) were enrolled. Eleven subjects (55%) had an elevated lactate dehydrogenase level, and 10 patients (50%) had International Prognostic Index scores of 3 to 5. Standard R-CHOP was administered on a 21-day cycle for 6 cycles, with 1 of 3 dose levels of bortezomib (0.7 mg/m2 [n = 4 patients], 1.0 mg/m2 [n = 9 patients], or 1.3 mg/m2 [n = 7 patients]) administered on Days 1 and 4 of each cycle.
The maximum tolerated dose of bortezomib with R-CHOP was not reached, and the 1.3-mg/m2 dose level had acceptable tolerability. A dose-limiting toxicity (pulmonary) was only observed in 1 patient receiving 1.0 mg/m2 of bortezomib. Neuropathy occurred in 13 patients (65%), but was mostly grade 1 (45%) and reached grade 3 in only 1 patient (all toxicities were graded using the Common Terminology Criteria for Adverse Events, version 3.0). Grade 4 hematologic toxicity occurred in 7 patients (35%). Of 19 evaluable patients, all responded, with 18 (95%) cases of complete response/complete response unconfirmed achieved and 1 (5%) partial response reported. At a median follow-up of 56 months, overall survival at 4 years was 75% and progression-free survival was 58%.
Bortezomib at a dose of 1.3 mg/m2 twice per cycle can be added to R-CHOP chemotherapy with acceptable toxicity. Multi-institutional and cooperative group follow-up studies of this regimen are currently ongoing. Cancer 2010. © 2010 American Cancer Society.